TY - JOUR
T1 - Docetaxel FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma
T2 - A Single-center Retrospective Cohort Study
AU - Umeki, Yusuke
AU - Matsuoka, Hiroshi
AU - Fujita, Masahiro
AU - Goto, Ai
AU - Serizawa, Akiko
AU - Nakamura, Kenichi
AU - Akimoto, Shingo
AU - Nakauchi, Masaya
AU - Tanaka, Tsuyoshi
AU - Shibasaki, Susumu
AU - Inaba, Kazuki
AU - Uyama, Ichiro
AU - Suda, Koichi
N1 - Publisher Copyright:
© 2023 Authors. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Objective The aim of this study was to determine the safety and clinical efficacy of docetaxel fluorouracil (DCF) as neoadjuvant chemotherapy (NAC). Methods In this single-center study, patient background and treatment outcomes (NAC efficacy assessment, NAC adverse events, short-term postoperative outcomes, and one-year postoperative outcomes) in patients treated with preoperative DCF and preoperative cisplatinFU (CF) were compared retrospectively. Patients Seventeen patients diagnosed with esophageal squamous cell carcinoma (ESCC) and treated with preoperative DCF therapy and 50 patients treated with preoperative CF therapy between January 2013 and July 2019 were included in this study. Results There were significant differences in clinical T factor and clinical stage between the CF and DCF groups (p<0.05). All patients in the DCF therapy group were above clinical T3 and clinical stage III. The clinical response after NAC was partial response (PR) for 23 patients (46.0%) in the CF group and 13 patients (76.5%) in the DCF group (p=0.030). Regarding adverse events in NAC, neutropenia, febrile neutropenia (FN), diarrhea, and stomatitis were observed more frequently in the DCF group than in the CF group (p<0.05). The postoperative results [overall survival (OS), recurrence-free survival (RFS), one-year OS, oneyear RFS] of the DCF group were comparable to those of the CF group. Conclusion DCF therapy has been recognized as an effective treatment option for advanced ESCC. However, the indication for DCF therapy should be chosen carefully because of the high incidence of adverse events.
AB - Objective The aim of this study was to determine the safety and clinical efficacy of docetaxel fluorouracil (DCF) as neoadjuvant chemotherapy (NAC). Methods In this single-center study, patient background and treatment outcomes (NAC efficacy assessment, NAC adverse events, short-term postoperative outcomes, and one-year postoperative outcomes) in patients treated with preoperative DCF and preoperative cisplatinFU (CF) were compared retrospectively. Patients Seventeen patients diagnosed with esophageal squamous cell carcinoma (ESCC) and treated with preoperative DCF therapy and 50 patients treated with preoperative CF therapy between January 2013 and July 2019 were included in this study. Results There were significant differences in clinical T factor and clinical stage between the CF and DCF groups (p<0.05). All patients in the DCF therapy group were above clinical T3 and clinical stage III. The clinical response after NAC was partial response (PR) for 23 patients (46.0%) in the CF group and 13 patients (76.5%) in the DCF group (p=0.030). Regarding adverse events in NAC, neutropenia, febrile neutropenia (FN), diarrhea, and stomatitis were observed more frequently in the DCF group than in the CF group (p<0.05). The postoperative results [overall survival (OS), recurrence-free survival (RFS), one-year OS, oneyear RFS] of the DCF group were comparable to those of the CF group. Conclusion DCF therapy has been recognized as an effective treatment option for advanced ESCC. However, the indication for DCF therapy should be chosen carefully because of the high incidence of adverse events.
KW - esophageal squamous cell carcinoma
KW - neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85147235757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147235757&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.9751-22
DO - 10.2169/internalmedicine.9751-22
M3 - Article
C2 - 36725064
AN - SCOPUS:85147235757
SN - 0918-2918
VL - 62
SP - 319
EP - 325
JO - Internal Medicine
JF - Internal Medicine
IS - 3
ER -